195 related articles for article (PubMed ID: 33988833)
1. Risk Minimization of Antibody-Drug Conjugates in Oncology: A Review.
Lievano FA; Scarazzini LJ; Tyczynski JE; Schubert CM; Renz CL
Drug Saf; 2021 Jul; 44(7):733-742. PubMed ID: 33988833
[TBL] [Abstract][Full Text] [Related]
2. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Zhu Y; Liu K; Wang K; Zhu H
Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the safety of antibody-drug conjugates for patients with solid tumours.
Tarantino P; Ricciuti B; Pradhan SM; Tolaney SM
Nat Rev Clin Oncol; 2023 Aug; 20(8):558-576. PubMed ID: 37296177
[TBL] [Abstract][Full Text] [Related]
6. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
7. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
8. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
[TBL] [Abstract][Full Text] [Related]
9. Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies.
Raheem F; Alsuhebany N; Hickey Zacholski E; Paulic N; Sandler A; Uk N; Moore DC
Expert Opin Drug Saf; 2023; 22(10):921-928. PubMed ID: 37612255
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates and Ocular Toxicity.
Jaffry M; Choudhry H; Aftab OM; Dastjerdi MH
J Ocul Pharmacol Ther; 2023 Dec; 39(10):675-691. PubMed ID: 37615544
[TBL] [Abstract][Full Text] [Related]
13. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
14. Toxicities From Antibody-Drug Conjugates.
Johns AC; Campbell MT
Cancer J; 2022 Nov-Dec 01; 28(6):469-478. PubMed ID: 36383910
[TBL] [Abstract][Full Text] [Related]
15. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
16. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
Amani N; Dorkoosh FA; Mobedi H
Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
18. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
19. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
